1 Department of Psychiatry, Yale University School of Medicine, West Haven, CT, USA.
2 Psychiatry Service, VA Connecticut Healthcare System, West Haven, CT, USA.
J Psychopharmacol. 2018 Dec;32(12):1308-1318. doi: 10.1177/0269881118799953. Epub 2018 Sep 26.
Binding studies have demonstrated that levels of the cannabinoid receptor type-1 are highest in the basal ganglia and cerebellum, two areas critical for motor control. However, no studies have systematically examined the dose-related effects of intravenous delta-9-tetrahydrocannabinol, the primary cannabinoid receptor type-1 partial agonist in cannabis, on broad domains of psychomotor function in humans.
Therefore, three domains of psychomotor function were assessed in former cannabis users (cannabis abstinent for a minimum of three months; n=23) in a three test-day, within-subject, double-blind, randomized, cross-over, and counterbalanced study during which they received intravenous delta-9-tetrahydrocannabinol (placebo, 0.015 mg/kg, and 0.03 mg/kg).
Gross motor function was assessed via the Cambridge Neuropsychological Test Automated Battery Motor Screening Task, fine motor control via the Lafayette Instrument Grooved Pegboard task, and motor timing via a Paced Finger-Tapping Task. In addition, the Cambridge Neuropsychological Test Automated Battery Rapid Visual Processing Task was utilized to determine whether delta-9-tetrahydrocannabinol-induced motor deficits were confounded by disruptions in sustained attention.
RESULTS/OUTCOMES: Delta-9-tetrahydrocannabinol resulted in robust dose-dependent deficits in fine motor control (Grooved Pegboard Task) and motor timing (Paced Finger-Tapping Task), while gross motor performance (Motor Screening Task) and sustained attention (Rapid Visual Processing Task) were unimpaired. Interestingly, despite the observed dose-dependent increases in motor impairment and blood levels of delta-9-tetrahydrocannabinol, subjects reported similar levels of intoxication in the two drug conditions.
CONCLUSIONS/INTERPRETATION: These data suggest that while several domains of motor function are disrupted by delta-9-tetrahydrocannabinol, subjective feelings of intoxication are dissociable from cannabinoid-induced psychomotor effects. Results are discussed in terms of the potential neural mechanisms of delta-9-tetrahydrocannabinol in motor structures.
结合研究已经证实,大麻素受体 1 的水平在基底神经节和小脑最高,这两个区域对运动控制至关重要。然而,目前还没有研究系统地检查静脉内给予 δ-9-四氢大麻酚(大麻中主要的大麻素受体 1 部分激动剂)对人类广泛的运动功能领域的剂量相关影响。
因此,在一项为期三天的、三测试日、在体、双盲、随机、交叉和平衡的研究中,评估了 23 名以前的大麻使用者(大麻戒断至少三个月)的三个运动功能领域,在此期间,他们接受了静脉内给予 δ-9-四氢大麻酚(安慰剂、0.015mg/kg 和 0.03mg/kg)。
采用剑桥神经心理学测试自动化电池运动筛查任务评估大运动功能,采用 Lafayette 仪器槽形插板任务评估精细运动控制,采用节拍手指敲击任务评估运动时间。此外,还利用剑桥神经心理学测试自动化电池快速视觉处理任务来确定 δ-9-四氢大麻酚引起的运动缺陷是否因持续注意力中断而复杂化。
结果/结论:δ-9-四氢大麻酚导致精细运动控制(槽形插板任务)和运动时间(节拍手指敲击任务)出现明显的剂量依赖性缺陷,而大运动表现(运动筛查任务)和持续注意力(快速视觉处理任务)则不受影响。有趣的是,尽管观察到运动损伤和 δ-9-四氢大麻酚血药水平的剂量依赖性增加,但在两种药物条件下,受试者报告的中毒程度相似。
这些数据表明,尽管几个运动功能领域都被 δ-9-四氢大麻酚破坏,但中毒的主观感觉与大麻素引起的精神运动效应是可分离的。结果从 δ-9-四氢大麻酚在运动结构中的潜在神经机制方面进行了讨论。